VEGFA and neoplasm: On the other hand, the results revealed that VEGF significantly diminished (p < 0.05) oestrogen circulating levels (E1SO4 and E2) and augmented tumour production; however, only celecoxib and bevacizumab significantly reduced (p < 0.05) E2 tumour homogenate concentrations.